TEAR LIPOCALIN MUTEINS, BINDING ALPHA IL-4 R Russian patent published in 2015 - IPC A61K38/20 C07K14/435 

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to novel muteins, obtained from human tear lipocalin, which bind with the IL-4 alpha-receptor. Sequences of the said muteins contain particular combinations of amino acids. In particular, a mutated amino acid residue is present at any one or more than one of positions 27, 28, 30, 31, 33, 53, 57, 61, 64, 66, 80, 83, 104-106 and 108 of the sequence of the linear polypeptide sequence of mature human tear lipocalin. The mutated amino acid residue is also present at any 2 or more than 2 of positions 26, 32, 34, 55, 56, 58 and 63 of the sequence of the linear polypeptide sequence of mature human tear lipocalin. Group of inventions also relates to respective molecule of nucleic acid, coding such mutein, and to a method of obtaining such mutein and molecule of nucleic acid that codes it.

EFFECT: group of inventions has improved binding properties with respect to the IL-4 alpha receptor, in particular higher binding affinity, which conditions their suitability in diagnostic and therapeutic applications.

14 cl, 5 dwg, 3 ex